In the REAL8 SGA substudy, weekly somapacitan was noninferior to both daily GH doses at one year and superior only to the lower-dose comparator.
Browsing: Landmark Trials in Endocrinology & Metabolism
Practice-changing landmark trials in endocrinology and metabolism, organized for rapid clinical review, exam preparation, teaching, and evidence-based patient care.
A pharmacokinetic crossover study and a four-week post hoc CAH subgroup analysis support biochemical effects, not established long-term clinical or safety benefits.
REAL8 found greater first-year height velocity with weekly somapacitan than daily GH in Noonan syndrome. Adult height and long-term safety remain separate questions.
BaxHTN found placebo-corrected systolic reductions of 8.7 and 9.8 mm Hg at 12 weeks. Review potassium events and why this differs from Bax24.
CARE-PWS did not meet its primary high-dose endpoints. Lower-dose hyperphagia findings were nominal secondary results, not a confirmatory efficacy success.
OASIS-3 tested elinzanetant for menopausal vasomotor symptoms. The primary week-12 result was positive; later symptom and sleep findings were descriptive.
A small randomised bone-biopsy study examined denosumab, teriparatide and their combination. Mechanistic findings do not establish superior fracture prevention.
foresiGHt found improved body composition with weekly lonapegsomatropin versus placebo in adult growth hormone deficiency. The daily comparator was descriptive.
ORBIT found no composite responders with secukinumab or placebo in active Graves orbitopathy. Read the PICO, limitations and clinical implications.
A double-blind crossover RCT compared prednisolone and hydrocortisone. Review the bone-marker results, secondary metabolic findings and important safety limitations.